Skip to content

Using virtual reality to treat social phobia

A comparative study of virtual reality versus in vivo exposure in the cognitive behavior treatment of social phobia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN99747069
Enrollment
45
Registered
2010-09-23
Start date
2010-09-18
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social phobia Mental and Behavioural Disorders Phobic anxiety disorders

Interventions

After receiving an appropriate diagnosis and completing the ethics procedures, participants will be randomly assigned to one of the following three conditions: 1. Tradd-CBT: Traditiona

Sponsors

Social Sciences and Humanities Research Council (Canada)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Ambulatory men and women 2. At least 18 years old and at most 65 years old 3. French speaking 4. Receiving a principal diagnosis of social anxiety disorder (SAD) according to DSM-IV-TR?s diagnostic criteria. Assessed at a psychiatric interview, standardized with the Structured Clinical Interview for DSM (SCID) 5. Suffering from SAD since at least two years 6. If currently taking medication for SAD, pharmacotherapy must be stabilized (same type and dosage) for at least six months and the social phobia remained stable and uncured (i.e., still meeting diagnostic criteria despite take the medication) Note that there is no perfect solution to the problem of medication since most severe cases already receive Selective Serotonin Reuptake Inhibitor (SSRI) from their doctors when they seek psychological treatments (thus, recruiting non-medicated participants would threaten the feasibility of the study and could lead to the selection of less severe cases) and stopping medication would induce other methodological problems (e.g., withdrawal symptoms, artificial peak of severity at pre-treatment, ethical issues).

Exclusion criteria

Exclusion criteria: 1. Currently suffering from a severe organic disease, dementia, mental retardation, schizophrenia, amnesia, psychosis or bipolar disorder 2. The SAD being secondary to any DSM-IV Axis-III diagnosis 3. Receiving any form of concurrent psychotherapy

Design outcomes

Primary

MeasureTime frame
Liebowitz Social Anxiety Scale (LSAS) It is a self-report consisting of 24 items that has been used in most of the recent outcome studies on SAD. Eleven items correspond to fear and avoidance of social interactions and 13 to performance fears. It is an excellent measure of SAD symptoms. Participant anxiety and avoidance are assessed. A total score is obtained, as well as fear and avoidance subscores. All outcomes will be assessed at baseline, post-treatment at at 6 month follow up.

Secondary

MeasureTime frame
1. Rathus Assertiveness Schedule This self-report measures social assertiveness. Thirty items, under the form of assertions concerning the way of behaving in different social situations, are proposed. The subject must indicate to which degree these assertions are typical of him/her and select one of the six possible answers ranging from +3 (really typical) to ?3 (really not typical). 2. Questionnaire on Social Contexts Inducing Anxiety This questionnaire enables to establish a typology of social anxieties (focused or generalized phobia, and type of subgroup: performance, assertiveness, intimacy or scrutiny anxiety) where the participant assesses the degree of her/his anxiety. 3. Behavior Avoidance Test Participants have to give an impromptu speech to a small audience (video recorded), for 6 minutes. Heart-rate variability and subjective anxiety are recorded and behavioral manifestations are coded by three independent assessors 'blind' to the hypotheses of the study. All outcomes will be assessed at baseline, post-treatment at at 6 month follow up.

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 28, 2026